RxDoctor Payments Data

Sumeet Chhabra, MD

Clinical Cardiac Electrophysiology · Plano, TXNPI 1548479827

Payments from drug & device makers

$66,475in general payments, 2019–2025

Across 464 payments — averaging $143.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$44K
  • Biosense Webster, Inc.$8K
  • Medtronic$8K
  • Medical Device Business Services, Inc.$2K
  • Boston Scientific$808
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$733
  • plus $3K from 33 others

What the payments were for

  • Consulting fees$29,79145%
  • Speaking & faculty fees$17,20026%
  • Travel & lodging$2,3794%
  • Food & beverage$17,10526%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,475 in reported general payments places this provider in the 65th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$544,521
Medicare patients
1,006
Services billed
7,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban406$520,481
XareltoRivaroxaban137$156,976
MultaqDronedarone Hcl22$27,135
Dofetilide74$11,346
Mexiletine Hcl31$3,861
Flecainide Acetate77$3,266
Metoprolol Succinate161$2,594
Amiodarone Hcl66$1,974
SotalolSotalol Hcl60$1,203
Esomeprazole Magnesium25$740
Propafenone Hcl18$673
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$457
Cephalexin89$447
Warfarin Sodium33$315
Verapamil ErVerapamil Hcl17$304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$371$520,481406 claims
Johnson & JohnsonXarelto$254$156,976137 claims
Sanofi-aventis U.S. LLCMultaq$151$27,13522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →